# Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

Study · id `cardio:ct-nct05105321` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05105321](<https://clinicaltrials.gov/study/NCT05105321>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05105321

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 5200 participants.

## Technical summary

Registry record NCT05105321. Randomized; triple masking; primary purpose prevention. Start 2021-12 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 5200 participants (planned count; ClinicalTrials.gov record NCT05105321, source copy `cardio:ctgov-nct05105321-2021-11-03`, retrieved 2026-10-26)
- Planned start: 2021-12 (anticipated) (ClinicalTrials.gov record NCT05105321, source copy `cardio:ctgov-nct05105321-2021-11-03`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05105321, source copy `cardio:ctgov-nct05105321-2021-11-03`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT05105321, source copy `cardio:ctgov-nct05105321-2021-11-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05105321, source copy `cardio:ctgov-nct05105321-2021-11-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05105321-2021-11-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
- Acronym: CDPP
- Condition: Metabolic Syndrome
- Intervention (Drug): Berberine
- Intervention (Behavioral): Healthy lifestyle intervention
- Lead sponsor: Tang Yida
- Lead sponsor class: OTHER
- Collaborator: Chinese Society of Cardiology
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Chinese Society of Cardiology (`cardio:org-chinese-society-of-cardiology`)

## Provenance

Content hash: b03b419117e4f4d3eafe3f6b55f36c60b295cf0c372e0400892bc10b8c4379ee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
